Second-generation antipsychotics in children: Risks and monitoring needs.
Lambert C, Panagiotopoulos C, Davidson J, Goldman RD. Second-generation antipsychotics in children: Risks and monitoring needs. Canadian Family Physician 2018, 64: 660-662. PMID: 30209096, PMCID: PMC6135131.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsChildDrug MonitoringGuideline AdherenceHumansMental DisordersMetabolic DiseasesPatient Acceptance of Health CareConceptsSide effectsSecond-generation antipsychotic treatmentSafety of antipsychoticsMetabolic side effectsSecond-generation antipsychoticsUse of SGAsEfficacy of treatmentPotential side effectsQuality of lifeAdjunctive metforminPediatric patientsMale patientsAntipsychotic treatmentFamily physiciansPhysical activityPatient's motherTherapeutic effortsHealthy eatingPatientsWeight gainSGAFamily practiceChildren guidelinesCanadian AlliancePotential role